Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
For the quarter ended June 2026, Johnson & Johnson posted earnings and revenue surprises versus expectations, according to a market report published July 15, 2026. The company’s update did not spell out how the beat was generated, leaving investors to parse what comes next.
THE APEX TIMES
THE APEX TIMES
A full-year outlook lift tied to stronger-than-expected second-quarter results was not enough to calm concerns around weakness in Stelara sales, even as oncology performance helped offset the decline.
THE APEX TIMES
The healthcare conglomerate reported results that beat expectations and increased its full-year guidance, even as JNJ stock slipped in early trading.
THE APEX TIMES
AdvanCell Pty, a biotechnology company supported by Eli Lilly and Co., has secured $315 million in new financing to advance an experimental cancer therapy, highlighting continued investor appetite for early-stage oncology science.
THE APEX TIMES
A fresh set of valuation assumptions has nudged the estimated fair value of HCA Healthcare down to about $490 per share from roughly $504, with the adjustment tied to concerns that health policy risks could weigh on the company’s outlook.
THE APEX TIMES
The company’s latest results beat Wall Street forecasts, yet investors sent Johnson & Johnson’s stock lower premarket as the market weighed what comes next.
THE APEX TIMES
The company said its latest quarter showed continued momentum from its product pipeline, and it increased its 2026 guidance.
THE APEX TIMES
The New Brunswick, New Jersey-based healthcare company’s board set the cash dividend at $1.34 per common share for the July-to-September quarter, a routine shareholder payout that outlines continued capital return.
THE APEX TIMES
A July 8 note from Barclays downgraded HCA Healthcare (NYSE:HCA) from Overweight to Equal Weight, a move highlighted in a market update dated July 15.
